Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
説明 | Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
Species | Human |
Expression Host | HEK293 Cells |
Tag | C-His-Avi |
Accession Number | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK |
別名 | KRAS1, C-K-RAS, K-RAS4B, RALD, K-Ras 2, K-RAS2A, K-RAS2B, KRAS2, NS3, KI-RAS, KRAS, RASK2, GTPase Kras, MHC, K-RAS4A, NS, CFC2 |
Construction | Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide |
Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Supplied as 0.22 μm filtered solution in PBS (pH 7.4). |
Stability & Storage |
Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping |
In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
Research Background | Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled KRAS1 C-K-RAS K-RAS4B RALD K-Ras 2 K-RAS2A K-RAS2B KRAS2 NS3 KI-RAS KRAS RASK2 GTPase Kras MHC K-RAS4A NS CFC2 recombinant recombinant-proteins proteins protein